Bevacizumab and Irinotecan therapy in recurrent malignant glioma, is it really effective?

J. Schroeteler, M. Rapp, G. Stoffels, H.J. Steiger, W. Stummer & M.C. Sabel
Objective: Despite extensive treatment with alkylating chemotherapy, most patients with malignant gliomas suffer from a recurrence within 12 months. We therefore decided to treat extensively pre-treated patients upon recurrence with Bevacizumab (B), an antibody against VEGF, and Irinotecan (I), a topoisomerase[for full text, please go to the a.m. URL]